KAE609 (Cipargamin), a new spiroindolone agent for the treatment of malaria: Evaluation of the Absorption, Distribution, Metabolism and Excretion of a single oral 300 mg dose of [14C]KAE609 in healthy male subjects

Data Supplement

Files in this Data Supplement:

• Supplemental Data -

  Materials and Methods

  Supplemental Table 1 - 1H- and 13C assignments of compound 3 and 4 and important HMBC correlations

  Supplemental Table 2 - Recovery of KAE609 and its metabolites in human urine following an oral dose of 300 mg 14C KAE609

  Supplemental Table 3 - Recovery of KAE609 and its metabolites in human feces (expressed as % of dose) following an oral dose of 300 mg 14C KAE609